Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory Pathway

MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the commencement of its first clinical trial for an antiparasitic drug candidate powered by Gelteq® technology, marking a significant milestone as the Company expands into the veterinary pharmaceutical sector. The clinical trial seeks to support Gelteq's planned FDA regulatory pathway for animal use, with the Company targeting a potential application later in 2026.